Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on December 8th, 2023%
The developer of an experimental immunotherapy delivering nanoscale payloads to treat pancreatic cancer says the treatment received fast-track status from the Food and Drug Administration. . . . → Read More: Nanotech Pancreatic Cancer Immunotherapy Gains FDA Fast Track
By Alan, on December 7th, 2023%
A developer of treatments for brain disorders and researchers at Stanford University aim to harness ultrasound to deliver drugs in nanoscale particles to precise regions of the brain. . . . → Read More: Biotech, Academic Labs Partner on Ultrasound Brain Therapy
By Alan, on November 28th, 2023%
A developer of messenger RNA therapies for respiratory and rare diseases says it received clearance to begin a clinical trial in the U.K. for an inhaled treatment for viral lung conditions. . . . → Read More: Trial Set to Test Inhaled mRNA for Viral Infections
By Alan, on October 20th, 2023%
A life science venture investor is merging two of its biotechnology portfolio companies to form a single developer of nanoscale medications with programmable properties. . . . → Read More: Merger to Form Programmable Nano-Medicines Company
By Alan, on October 17th, 2023%
A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler. . . . → Read More: Start-Up Adapts Crispr for Molecular Detection, Raises $40M
By Alan, on August 16th, 2023%
A clinical trial has begun testing an experimental treatment for burns using off-the-shelf therapeutic particles derived from human bone marrow stem cells. . . . → Read More: Trial Underway Testing Stem Cell Particles for Burns
By Alan, on July 27th, 2023%
A group of academic and industry researchers exhibited in lab cells and mice a more direct delivery technique that could make gene therapies more accessible and inexpensive. . . . → Read More: Streamlined Gene Therapy Delivery Process Demonstrated
By Alan, on June 7th, 2023%
A developer of nanoscale lipid particles for delivering genomic therapies to specific cells and tissue, spun-off from academic labs, is raising $25 million in seed funds. . . . → Read More: Targeted Genetic Nanoparticle Company Gains $25M in Seed Funds
By Alan, on April 27th, 2023%
Ultra-low quantities of an experimental Covid-19 protein vaccine delivered in synthetic cell components are shown in lab animals to generate strong immune responses. . . . → Read More: Low-Dose Covid-19 Vaccine Generates Strong Immune Response
By Alan, on April 11th, 2023%
A start-up company with a process for harvesting large quantities of cells that infiltrate and kill solid tumors is raising $10 million in seed venture funds. . . . → Read More: Cancer Cell Therapy Biotech Launches, Raises $10M
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|